Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Metabolic Parameters, Weight Loss, and Comorbidities 4 Years After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy.

Lager CJ, Esfandiari NH, Luo Y, Subauste AR, Kraftson AT, Brown MB, Varban OA, Meral R, Cassidy RB, Nay CK, Lockwood AL, Bellers D, Buda CM, Oral EA.

Obes Surg. 2018 Jun 16. doi: 10.1007/s11695-018-3346-1. [Epub ahead of print]

PMID:
29909517
2.

Renal complications of lipodystrophy: A closer look at the natural history of kidney disease.

Akinci B, Unlu SM, Celik A, Simsir IY, Sen S, Nur B, Keskin FE, Ozgen Saydam B, Kutbay Ozdemir N, Sarer Yurekli B, Ergur BU, Sonmez M, Atik T, Arslan A, Demir T, Altay C, Tunc UA, Arkan T, Gen R, Eren E, Akinci G, Yilmaz AA, Bilen H, Ozen S, Celtik A, Savas Erdeve S, Cetinkaya S, Onay H, Sarioglu S, Oral EA.

Clin Endocrinol (Oxf). 2018 Jul;89(1):65-75. doi: 10.1111/cen.13732. Epub 2018 May 17.

PMID:
29722904
3.

Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.

Brown RJ, Oral EA, Cochran E, Araújo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Gorden P.

Endocrine. 2018 Jun;60(3):479-489. doi: 10.1007/s12020-018-1589-1. Epub 2018 Apr 12.

PMID:
29644599
4.

Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis.

Sahinoz M, Khairi S, Cuttitta A, Brady GF, Rupani A, Meral R, Tayeh MK, Thomas P, Riebschleger M, Camelo-Piragua S, Innis JW, Bishr Omary M, Michele DE, Oral EA.

Clin Diabetes Endocrinol. 2018 Mar 27;4:6. doi: 10.1186/s40842-018-0058-3. eCollection 2018.

5.

Lamin A/C Maintains Exocrine Pancreas Homeostasis by Regulating Stability of RB and Activity of E2F.

Elenbaas JS, Bragazzi Cunha J, Azuero-Dajud R, Nelson B, Oral EA, Williams JA, Stewart CL, Omary MB.

Gastroenterology. 2018 May;154(6):1625-1629.e8. doi: 10.1053/j.gastro.2018.01.024. Epub 2018 Jan 31.

PMID:
29366840
6.

A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation.

Hussain I, Patni N, Ueda M, Sorkina E, Valerio CM, Cochran E, Brown RJ, Peeden J, Tikhonovich Y, Tiulpakov A, Stender SRS, Klouda E, Tayeh MK, Innis JW, Meyer A, Lal P, Godoy-Matos AF, Teles MG, Adams-Huet B, Rader DJ, Hegele RA, Oral EA, Garg A.

J Clin Endocrinol Metab. 2018 Mar 1;103(3):1005-1014. doi: 10.1210/jc.2017-02078.

PMID:
29267953
7.

Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study.

Kumar A, Blackshear C, Subauste JS, Esfandiari NH, Oral EA, Subauste AR.

J Endocr Soc. 2017 Mar 22;1(5):460-469. doi: 10.1210/js.2017-00055. eCollection 2017 May 1.

8.

Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges.

Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P.

Diabetes Metab Syndr Obes. 2017 Sep 13;10:375-383. doi: 10.2147/DMSO.S130810. eCollection 2017.

9.

Roux-en-Y gastric bypass versus sleeve gastrectomy: risks and benefits.

Ettleson MD, Lager CJ, Kraftson AT, Esfandiari NH, Oral EA.

Minerva Chir. 2017 Dec;72(6):505-519. doi: 10.23736/S0026-4733.17.07441-7. Epub 2017 Jul 26.

PMID:
28749117
10.

Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.

Oral EA, Reilly SM, Gomez AV, Meral R, Butz L, Ajluni N, Chenevert TL, Korytnaya E, Neidert AH, Hench R, Rus D, Horowitz JF, Poirier B, Zhao P, Lehmann K, Jain M, Yu R, Liddle C, Ahmadian M, Downes M, Evans RM, Saltiel AR.

Cell Metab. 2017 Jul 5;26(1):157-170.e7. doi: 10.1016/j.cmet.2017.06.006.

PMID:
28683283
11.

Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.

Akinci B, Onay H, Demir T, Savas-Erdeve Ş, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, Yaylali GF, Ozdemir NK, Atik T, Ozen S, Yurekli BS, Apaydin T, Altay C, Akinci G, Demir L, Comlekci A, Secil M, Oral EA.

Metabolism. 2017 Jul;72:109-119. doi: 10.1016/j.metabol.2017.04.010. Epub 2017 Apr 27.

PMID:
28641778
12.

Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression.

Rocha N, Bulger DA, Frontini A, Titheradge H, Gribsholt SB, Knox R, Page M, Harris J, Payne F, Adams C, Sleigh A, Crawford J, Gjesing AP, Bork-Jensen J, Pedersen O, Barroso I, Hansen T, Cox H, Reilly M, Rossor A, Brown RJ, Taylor SI, McHale D, Armstrong M, Oral EA, Saudek V, O'Rahilly S, Maher ER, Richelsen B, Savage DB, Semple RK.

Elife. 2017 Apr 19;6. pii: e23813. doi: 10.7554/eLife.23813.

13.

Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort.

Ajluni N, Meral R, Neidert AH, Brady GF, Buras E, McKenna B, DiPaola F, Chenevert TL, Horowitz JF, Buggs-Saxton C, Rupani AR, Thomas PE, Tayeh MK, Innis JW, Omary MB, Conjeevaram H, Oral EA.

Clin Endocrinol (Oxf). 2017 May;86(5):698-707. doi: 10.1111/cen.13311. Epub 2017 Mar 27.

14.

Milestone Weight Loss Goals (Weight Normalization and Remission of Obesity) after Gastric Bypass Surgery: Long-Term Results from the University of Michigan.

Lager CJ, Esfandiari NH, Subauste AR, Kraftson AT, Brown MB, Cassidy RB, Bellers D, Lockwood AL, Varban OA, Oral EA.

Obes Surg. 2017 Jul;27(7):1659-1666. doi: 10.1007/s11695-016-2533-1.

PMID:
28084587
15.

The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T.

J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. Epub 2016 Oct 6. Review.

16.

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.

Oral EA.

Drugs Context. 2016 Sep 2;5:212299. doi: 10.7573/dic.212299. eCollection 2016. Review.

17.

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.

Ajluni N, Dar M, Xu J, Neidert AH, Oral EA.

J Diabetes Metab. 2016 Mar;7(3). pii: 659. Epub 2016 Mar 23.

18.

Roux-En-Y Gastric Bypass Vs. Sleeve Gastrectomy: Balancing the Risks of Surgery with the Benefits of Weight Loss.

Lager CJ, Esfandiari NH, Subauste AR, Kraftson AT, Brown MB, Cassidy RB, Nay CK, Lockwood AL, Varban OA, Oral EA.

Obes Surg. 2017 Jan;27(1):154-161. doi: 10.1007/s11695-016-2265-2.

19.

Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome.

Walden P, Jiang Q, Jackson EA, Oral EA, Weintraub MS, Rubenfire M.

Diabetes Metab Syndr Obes. 2016 Jun 1;9:177-84. doi: 10.2147/DMSO.S94772. eCollection 2016.

20.

Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.

Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ.

Clin Endocrinol (Oxf). 2016 Jul;85(1):137-49. doi: 10.1111/cen.12980. Epub 2016 Feb 2.

Supplemental Content

Loading ...
Support Center